New research has found that treatment with metformin is significantly linked with reduced mortality in people with Type 2 diabetes, compared with treatment with other anti-diabetes drug classes. Treatment with a sodium-glucose cotransporter 2 inhibitor (SGLT2i) was also found to be significantly associated with increased longevity, compared with treatment with other glucose-lowering medications. The survival of people with Type 2 diabetes on SGLT2i treatment approximated that of people without diabetes, and SGLT2i treatment was also linked with significantly lower cancer-related mortality. These results should encourage clinicians to consider metformin and an SGLT2i agent for either single- or dual-drug first-line treatment of people with Type 2 diabetes.
To read more, CLICK HERE.